Saturday, October 31, 2026
ExploreSearch
Via News
Marketstock

FuboTV Stock Impressive Jump On Thursday, Outperforms Market

ViaNews Editorial Team

September 7, 2023

FuboTV Stock Impressive Jump On Thursday, Outperforms Market

(VIANEWS) - The NYSE ended the session with FuboTV rising 10.04% to $2.96 on Thursday, after two successive sessions in a row of losses. NYSE dropped 0.17% to $15,864.19, after two sequential sessions in a row of losses, on what was a somewhat negative trend trading session today.

About FuboTV

fuboTV Inc. operates a live TV streaming platform for live sports, news, and entertainment content in the United States and internationally. Its fuboTV platform allows customers to access content through streaming devices, as well as on SmartTVs, computers, mobile phones, and tablets. The company is headquartered in New York, New York.

Earnings Per Share

As for profitability, FuboTV has a trailing twelve months EPS of $-1.77.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, FuboTV's stock is considered to be oversold (<=20).

Sales Growth

FuboTV's sales growth is 33.4% for the ongoing quarter and 19% for the next.

More news about FuboTV (FUBO).

Categories

Marketstock

Tags

Stock MarketStockWall StreetStock PriceStock Market NowNYSENYAThe New York Stock ExchangeStock Price UpFuboTVFUBOPrice UpMarket CloseEnd of DayClosesMarket-Close Nowintelligent
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com